MetaVia Inc. (MTVA)
NASDAQ: MTVA · Real-Time Price · USD
0.7898
-0.0201 (-2.48%)
At close: May 23, 2025, 4:00 PM
0.7901
+0.0003 (0.04%)
After-hours: May 23, 2025, 4:25 PM EDT
MetaVia Employees
MetaVia had 9 employees as of December 31, 2024. The number of employees increased by 1 or 12.50% compared to the previous year.
Employees
9
Change (1Y)
1
Growth (1Y)
12.50%
Revenue / Employee
n/a
Profits / Employee
-$2,727,667
Market Cap
6.84M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
MTVA News
- 9 days ago - MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 14 days ago - MetaVia Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules - PRNewsWire
- 16 days ago - MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025 - PRNewsWire
- 4 weeks ago - MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025 - PRNewsWire
- 4 weeks ago - MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class Potential - PRNewsWire
- 5 weeks ago - MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and Tolerability - PRNewsWire
- 2 months ago - MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update - PRNewsWire
- 4 months ago - MetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 Conference - PRNewsWire